An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany

BACKGROUND: This study aimed to evaluate cost-utility of baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Borisenko, Oleg, Müller-Ehmsen, Jochen, Lindenfeld, JoAnn, Rafflenbeul, Erik, Hamm, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085633/
https://www.ncbi.nlm.nih.gov/pubmed/30092774
http://dx.doi.org/10.1186/s12872-018-0898-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085633/
https://www.ncbi.nlm.nih.gov/pubmed/30092774
http://dx.doi.org/10.1186/s12872-018-0898-x

Ejemplares similares